Generically known as Imatinib Mesylate, Gleevec is a protein-tyrosine kinase inhibitor that is prescribed for Philadelphia chromosome-positive Chronic Myeloid Leukemia (CML).
|
Chronic Myeloid Leukiemia (also known as CML or Chronic Myelogenous Leukemia) is a disease in which the bone marrow makes too many white blood cells. Most people with CML have a gene mutation called the Philadelphia chromosome. Learn more about the disease:
|
Learn more about pathways of normal vs. diseased people and how Gleevec interacts with that pathway (shown below).
|
A study was published in the American Journal of Clinical Pathology examining the effects of Gleevec on Chronic Myeloid Leukemia patients. You can read the full article here or read a summary on our website.
|